[go: up one dir, main page]

WO2011095985A3 - Rasagiline salts and processes for the preparation thereof - Google Patents

Rasagiline salts and processes for the preparation thereof Download PDF

Info

Publication number
WO2011095985A3
WO2011095985A3 PCT/IN2011/000059 IN2011000059W WO2011095985A3 WO 2011095985 A3 WO2011095985 A3 WO 2011095985A3 IN 2011000059 W IN2011000059 W IN 2011000059W WO 2011095985 A3 WO2011095985 A3 WO 2011095985A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
preparation
rasagiline salts
rasagiline
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000059
Other languages
French (fr)
Other versions
WO2011095985A2 (en
Inventor
Sunil Sudhakar Zope
Colony Deshmukh
Laxmikant Madhukar Kelkar
Joseph Prabahar Koilpillai
Milind Moreshwar Gharpure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Generics Ltd
Original Assignee
Glenmark Generics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Generics Ltd filed Critical Glenmark Generics Ltd
Publication of WO2011095985A2 publication Critical patent/WO2011095985A2/en
Publication of WO2011095985A3 publication Critical patent/WO2011095985A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to crystalline salts of rasagiline and processes for the preparation thereof. The invention also relates to pharmaceutical compositions comprising the same.
PCT/IN2011/000059 2010-02-02 2011-01-28 Rasagiline salts and processes for the preparation thereof Ceased WO2011095985A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN242/MUM/2010 2010-02-02
IN242MU2010 2010-02-02

Publications (2)

Publication Number Publication Date
WO2011095985A2 WO2011095985A2 (en) 2011-08-11
WO2011095985A3 true WO2011095985A3 (en) 2011-12-22

Family

ID=44355887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000059 Ceased WO2011095985A2 (en) 2010-02-02 2011-01-28 Rasagiline salts and processes for the preparation thereof

Country Status (1)

Country Link
WO (1) WO2011095985A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231054B1 (en) * 2010-11-18 2020-04-28 Egis Gyógyszergyár Nyrt. Novel salts suitable for the preparation of pharmaceutical compositions
WO2012153349A2 (en) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
DE102012000786A1 (en) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Process for the preparation of a solid pharmaceutical composition containing the active substance rasagiline
CN111983075A (en) * 2020-08-17 2020-11-24 重庆华森制药股份有限公司 Method for detecting rasagiline and enantiomer thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532415A (en) * 1990-01-03 1996-07-02 Teva Pharmaceutical Industries Ltd. R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US6959060B2 (en) * 2000-08-31 2005-10-25 Lg Electronics Inc. Jitter reducing apparatus using digital modulation technique
CN1911211A (en) * 2006-08-25 2007-02-14 重庆医药工业研究院有限责任公司 Solid oral prepn. of leishajilan
CN101600346A (en) * 2006-12-14 2009-12-09 泰华制药工业有限公司 Tannate of rasagiline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532415A (en) * 1990-01-03 1996-07-02 Teva Pharmaceutical Industries Ltd. R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US6959060B2 (en) * 2000-08-31 2005-10-25 Lg Electronics Inc. Jitter reducing apparatus using digital modulation technique
CN1911211A (en) * 2006-08-25 2007-02-14 重庆医药工业研究院有限责任公司 Solid oral prepn. of leishajilan
CN101600346A (en) * 2006-12-14 2009-12-09 泰华制药工业有限公司 Tannate of rasagiline

Also Published As

Publication number Publication date
WO2011095985A2 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2011130615A3 (en) Preparation of lacosamide
WO2010092090A3 (en) Novel salts of sitagliptin
WO2014014835A3 (en) Criystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2012042371A3 (en) Pharmaceutical composition
WO2011138281A3 (en) Process for the preparation of dithiine tetracarboxydiimides
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
WO2011157720A3 (en) Ivabradine-containing pharmaceutical composition with modified release
WO2012021715A3 (en) Stable formulations of linaclotide
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2014072961A3 (en) Polymorphic forms of suvoroxant
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2013055684A8 (en) Rasagiline citramide
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2014068586A3 (en) Solid oral compositions of tolvaptan
WO2010008735A3 (en) Solid states of o-desmethylvenlaf axine salts
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
HK1201067A1 (en) Sialic acid analogs
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
PH12013500210A1 (en) Highly crystalline valsartan

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11739499

Country of ref document: EP

Kind code of ref document: A2